Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AxoGen stock | 15.11

Own AxoGen stock in just a few minutes.


Fact checked

AxoGen, Inc is a medical devices business based in the US. AxoGen shares (AXGN) are listed on the NASDAQ and all prices are listed in US Dollars. AxoGen employs 371 staff and has a trailing 12-month revenue of around USD$103.1 million.

How to buy shares in AxoGen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AxoGen. Find the stock by name or ticker symbol: AXGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AxoGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$15.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AxoGen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AxoGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AxoGen's share price?

Since the stock market crash in March caused by coronavirus, AxoGen's share price has had significant positive movement.

Its last market close was USD$15.11, which is 2.71% up on its pre-crash value of USD$14.7 and 94.72% up on the lowest point reached during the March crash when the shares fell as low as USD$7.76.

If you had bought USD$1,000 worth of AxoGen shares at the start of February 2020, those shares would have been worth USD$685.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,188.85.

AxoGen share price

Use our graph to track the performance of AXGN stocks over time.

AxoGen shares at a glance

Information last updated 2020-10-20.
Latest market close USD$15.11
52-week range USD$7.16 - USD$18.84
50-day moving average USD$12.1374
200-day moving average USD$10.5217
Wall St. target price USD$16.6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.666

Buy AxoGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AxoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AxoGen price performance over time

Historical closes compared with the close of $15.11 from 2020-11-16

1 week (2020-11-24) 4.79%
1 month (2020-10-30) 19.83%
3 months (2020-09-01) 23.15%
6 months (2020-06-01) 55.45%
1 year (2019-11-29) -12.81%
2 years (2018-11-30) -54.87%
3 years (2017-12-01) -42.77%
5 years (2015-12-01) 174.73%

AxoGen financials

Revenue TTM USD$103.1 million
Gross profit TTM USD$89.4 million
Return on assets TTM -11.3%
Return on equity TTM -22.43%
Profit margin -28.04%
Book value $2.992
Market capitalisation USD$538.7 million

TTM: trailing 12 months

Shorting AxoGen shares

There are currently 1.0 million AxoGen shares held short by investors – that's known as AxoGen's "short interest". This figure is 11.4% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting AxoGen shares can be evaluated.

AxoGen's "short interest ratio" (SIR)

AxoGen's "short interest ratio" (SIR) is the quantity of AxoGen shares currently shorted divided by the average quantity of AxoGen shares traded daily (recently around 342179.19463087). AxoGen's SIR currently stands at 2.98. In other words for every 100,000 AxoGen shares traded daily on the market, roughly 2980 shares are currently held short.

However AxoGen's short interest can also be evaluated against the total number of AxoGen shares, or, against the total number of tradable AxoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AxoGen's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AxoGen shares in existence, roughly 30 shares are currently held short) or 0.0311% of the tradable shares (for every 100,000 tradable AxoGen shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AxoGen.

Find out more about how you can short AxoGen stock.

AxoGen share dividends

We're not expecting AxoGen to pay a dividend over the next 12 months.

Have AxoGen's shares ever split?

AxoGen's shares were split on a 105:100 basis on 11 July 1994. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your AxoGen shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for AxoGen shares which in turn could have impacted AxoGen's share price.

AxoGen share price volatility

Over the last 12 months, AxoGen's shares have ranged in value from as little as $7.16 up to $18.84. A popular way to gauge a stock's volatility is its "beta".

AXGN.US volatility(beta: 0.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AxoGen's is 0.6944. This would suggest that AxoGen's shares are less volatile than average (for this exchange).

AxoGen overview

AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site